Martin Fitchet
Martin Fitchet is the Chief Executive Officer of Medicines for Malaria Venture (MMV), an organization dedicated to reducing the burden of malaria worldwide. With a focus on developing new treatments and strategies to combat malaria, Fitchet emphasizes the importance of collaboration and innovation in addressing this global health challenge. Under his leadership, MMV has made significant strides in creating effective malaria medicines, particularly for vulnerable populations, such as young children and infants.
Not in the pool (under ¢1).
Recent news mentions
Fitchet described the approval of Coartem Baby as a necessary medicine for treating neglected patients.
New infant malaria drug, vaccines light path to hope
Kenya· 2025-12-23
Dr. Martin Fitchet, MMV’s CEO, described the new formulations as transformational.
WHO Approves First Child-Friendly Malaria Drug — A Major Boost for Malawi’s Fight Against the Killer Disease - Malawi Nyasa Times
Malawi· 2025-11-20
MMV CEO Martin Fitchet said, 'Malaria is one of the world’s deadliest diseases, particularly among children.'
Kenya takes part in trials of first malaria treatment for newbornsKenya· 2025-07-15
Martin Fitchet, CEO of MMV, says this is another important step on the road towards ending the huge toll taken by malaria.
First malaria treatment for babies approved for use
Ghana· 2025-07-08
Martin Fitchet, CEO of MMV, describes the approval of Coartem Baby as an important step towards ending the toll taken by malaria.
First malaria vaccine for babies approved for use
United Kingdom· 2025-07-08